Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Cancer in a Drop: Liquid biopsy insights from AACR 2026. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer in a drop: advances in liquid biopsy in 2024
10.1016/j.critrevonc.2025.104776 · 2025 · External reference
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
10.1038/s41568-025-00795-x · 2025 · External reference
Unresolved reference
2026 · External reference
Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: systematic review and meta-analysis of diagnostic accuracy
10.1016/j.critrevonc.2026.105289 · 2026 · External reference
Genomic signatures in red blood cell DNA enable early non-invasive detection of colorectal neoplasia: a multicenter clinical study [abstract]
2026 · External reference
Urinary extracellular vesicle microRNA profiling enables noninvasive early detection and prognostic stratification of lung cancer [abstract]
2026 · External reference
Non-invasive early detection of cancer-predisposing liver diseases using genome-wide cfDNA fragmentomes [abstract]
2026 · External reference
Enhanced early detection of pancreatic cancer using a multi-analyte liquid biopsy approach [abstract]
2026 · External reference
Valsamo (Elsa) Anagnostou. Serial plasma comprehensive genomic profiling detects therapy resistance and guides management of metastatic non-small cell lung cancer [abstract]
2026 · External reference
Circulating tumor DNA (ctDNA) clearance dynamics in microsatellite instability-high metastatic (MSI-H) colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI) [abstract]
2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2024 · External reference
Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay [abstract]
2026 · External reference
Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): the MERIDIAN Phase II trial [abstract]
2026 · External reference
ctDNA clearance as a prognostic biomarker in ES-SCLC: insights from the LUMINANCE phase IIIb study [abstract]
2026 · External reference
ctDNA as a prognostic and pharmacodynamic biomarker following first- or later-line treatment of advanced NSCLC with BNT116 + cemiplimab [abstract]
2026 · External reference
Unresolved reference
2026 · External reference
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: results from a phase 1/2 study [abstract]
2026 · External reference
AXL mRNA overexpression in CTCs as a new potential liquid biopsy biomarker in NSCLC [abstract]
2026 · External reference
Circulating tumor cell (CTC) informed pipeline for rapid personalization of synergistic cytokine-armed CAR-NK cell therapy in PDAC [abstract]
2026 · External reference
Computational ranking-guided discovery of Plexin-B2 as a driver of circulating tumor cell clusters and AI-facilitated neutralization to prevent and inhibit metastasis [abstract]
2026 · External reference
Liquid biopsies come of age: towards implementation of circulating tumour DNA
10.1038/nrc.2017.7 · 2017 · External reference
Circulating mutant DNA to assess tumor dynamics
10.1038/nm.1789 · 2008 · External reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · 2013 · External reference
Integrating liquid biopsies into the management of cancer
10.1038/nrclinonc.2017.14 · 2017 · External reference
Current and future perspectives of liquid biopsies in genomics-driven oncology
10.1038/s41576-018-0071-5 · 2019 · External reference
Molecular profiling across 80,000 patients with lung cancer
10.1016/j.jtho.2026.103695 · 2026 · External reference
Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies
2025 · External reference
Feasibility of plasma ctDNA for detecting brain metastasis-specific alterations in lung cancer [abstract]
2026 · External reference
A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: circulating biomarkers and molecular correlates of clinical outcomes [abstract]
2026 · External reference
Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+/HER2− metastatic breast cancer [abstract]
2026 · External reference
